HMGA2 and ovarian carcinoma: Taken together, these results indicate that disrupting the INAVA–HMGA2 interaction with a cell‐permeable peptide suppresses NOF activation in vitro, and growth and metastasis of ovarian cancer in vivo, and may, therefore, be a promising therapeutic strategy for patients with ovarian cancer.